公开(公告)号：US11434301B2

公开(公告)日：2022-09-06

申请号：US16348135

申请日：2017-11-10

Applicant: The Regents of the University of California

Inventor： Bin Liu ,  Daniel W. Sherbenou ,  Blake T. Aftab ,  Yang Su ,  Christopher R. Behrens

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  C12Q1/6886 ,  C07K16/00 ,  G01N33/574 ,  A61K39/00

Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.

公开(公告)号：US20230383005A1

公开(公告)日：2023-11-30

申请号：US17815514

申请日：2022-07-27

Applicant: The Regents of the University of California

Inventor： Bin Liu ,  Daniel W. Sherbenou ,  Blake T. Aftab ,  Yang Su ,  Christopher R. Behrens

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  C12Q1/6886 ,  C07K16/00 ,  G01N33/574

CPC classification number: C07K16/2896 ,  A61K47/6809 ,  A61K47/6849 ,  A61K47/6813 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3069 ,  C12Q1/6886 ,  A61K47/6803 ,  C07K16/00 ,  G01N33/57492 ,  A61K2039/55

Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.

公开(公告)号：US20140161819A1

公开(公告)日：2014-06-12

申请号：US14098710

申请日：2013-12-06

Applicant: The Regents of the University of California ,  SANOFI

Inventor： Byron C. Hann ,  Blake Tomkinson ,  Thomas G. Martin, III ,  Blake T. Aftab

IPC: A61K39/395 ,  A61K31/45 ,  A61K45/06

CPC classification number: A61K39/39558 ,  A61K31/37 ,  A61K31/45 ,  A61K31/454 ,  A61K31/573 ,  A61K31/616 ,  A61K31/727 ,  A61K45/06 ,  A61K31/00 ,  A61K2300/00

Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

Abstract translation: 本文公开了包含抗CD38抗体和来那度胺化合物的组合物和试剂盒。 还公开了在具有组合物和试剂盒的受试者中治疗癌症如多发性骨髓瘤的方法。

公开(公告)号：US20190276553A1

公开(公告)日：2019-09-12

申请号：US16348135

申请日：2017-11-10

Applicant: The Regents of the University of California

Inventor： Bin Liu ,  Daniel W. Sherbenou ,  Blake T. Aftab ,  Yang Su ,  Christopher R. Behrens

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30 ,  C12Q1/6886 ,  A61K47/68

Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.

公开(公告)号：US10342869B2

公开(公告)日：2019-07-09

申请号：US14098710

申请日：2013-12-06

Applicant: SANOFI ,  The Regents of the University of California

Inventor： Byron C. Hann ,  Blake Tomkinson ,  Thomas G. Martin, III ,  Blake T. Aftab

IPC: A61K39/395 ,  A61K31/45 ,  A61K45/06 ,  A61K31/37 ,  A61K31/454 ,  A61K31/573 ,  A61K31/616 ,  A61K31/727

Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

公开(公告)号：US12252746B2

公开(公告)日：2025-03-18

申请号：US17815514

申请日：2022-07-27

Applicant: The Regents of the University of California

Inventor： Bin Liu ,  Daniel W. Sherbenou ,  Blake T. Aftab ,  Yang Su ,  Christopher R. Behrens

IPC: C12Q1/6886 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.